Microbot Medical Launches LIBERTY Full Market Release, but Adoption Evidence Still Lacking

What happened

Microbot Medical has begun the full U.S. launch of its LIBERTY endovascular robotic system, as reported in a recent news article citing strong hospital adoption. This aligns with the company's planned Full Market Release in Q2 2026, following a Limited Market Release initiated in November 2025. However, the DeepValue master report reveals only one publicly disclosed hospital adopter, Emory University Hospital, with no evidence of additional sites or procedure volumes to support the 'strong adoption' claim. Financially, Microbot remains pre-revenue with negative free cash flow and faces dilution risks from Series J options at a $4.50 strike price, which could pressure per-share value if the stock stays below that level. Thus, while the launch marks a procedural milestone, it does not yet demonstrate the commercial traction needed to de-risk the investment thesis.

Implication

The full launch progression keeps Microbot on its commercialization timeline but does not provide new data on hospital uptake or recurring revenue, leaving valuation speculative. Without disclosed multi-site adoptions or procedure metrics, the stock's price remains vulnerable to disappointment and potential dilutive financings if adoption lags. The Series J option overhang at $4.50 adds a technical ceiling, requiring sustained share price appreciation to avoid punitive equity raises. Monitoring should focus on upcoming quarterly disclosures for evidence of paying hospital sites and disposable usage by late 2026. Until such proof emerges, the high-risk profile justifies the 'WAIT' rating, with better entry opportunities likely after commercial validation.

Thesis delta

The launch news does not shift the fundamental thesis, as it was anticipated and lacks new evidence on adoption or financial performance. It underscores that the critical commercialization phase is now active, but investors must still wait for concrete metrics like multiple paying hospitals to reassess the risk-reward. No change is warranted until Microbot discloses meaningful revenue or site expansion beyond the single known adopter.